Skip to content

Ginkgo Bioworks DNA Investment Proceeds

Investment Proceeds at other companies

TEC
Bio-TechneTECH
$1.09M-95.4%
Azenta logo
AzentaAZTA
-$142.66M
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$145.1M-15.2%
Danaher logo
DanaherDHR
$0-100%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$175.5K
GeneDx Holdings logo
GeneDx HoldingsWGS
$875K

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's investment proceeds?
Ginkgo Bioworks (DNA) reported investment proceeds of $108.18M in Q1 2026.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.